The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.
 
Rona D. Yaeger
Consulting or Advisory Role - Amgen
Research Funding - Genentech; Novartis
 
Andrea Cercek
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics (I)
Research Funding - Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst)
 
Diane Lauren Reidy
Consulting or Advisory Role - Ipsen; Novartis; Pfizer
Research Funding - Novartis
 
Nancy E. Kemeny
Research Funding - Amgen
 
Tamar Wolinsky
No Relationships to Disclose
 
Marc J. Gollub
No Relationships to Disclose
 
Mario E. Lacouture
Consulting or Advisory Role - Amgen; Genentech; Roche
 
Neal Rosen
Stock and Other Ownership Interests - Wellspring
Honoraria - Chugai Pharma
Consulting or Advisory Role - AstraZeneca; Celgene; Chugai Pharma; Novartis; Takeda
Research Funding - Bayer; Chugai Pharma
 
Efsevia Vakiani
No Relationships to Disclose
 
Leonard Saltz
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer; Boehringer Ingelheim; pfizer; Roche/Genentech; Sun Pharma
Research Funding - Taiho Pharmaceutical